Literature DB >> 8697635

Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection.

W O Böcher1, S Herzog-Hauff, W Herr, K Heermann, G Gerken, K H Meyer Zum Büschenfelde, H F Löhr.   

Abstract

Antibodies directed to the HBs antigen indicate viral clearance and the development of life-long immunity in patients that recovered from HBV infection. In HBs antigen vaccine recipients anti-HBs antibodies provide protective immunity. However, little is known about the regulation of this HBs-specific antibody response. The existence of anti-HBs-secreting B cells was demonstrated using the highly sensitive ELISPOT technique compared with conventional ELISA in serum and cell culture supernatants. In the peripheral blood of patients with acute self-limited hepatitis B, HBs-specific B cells were demonstrated with a high frequency despite undetectable anti-HBs serum antibodies. HBV-immunized patients that had recovered from infection and vaccine recipients had significantly lower frequencies, whereas chronic HBV carriers and negative controls showed no anti-HBs-secreting B cells. Coculture experiments of isolated B and T cells revealed that the anti-HBs antibody response was restricted to the presence of T helper cells, but not to identical HLA class II molecules. Allogeneic T cells derived from vaccine recipients or chronic HBV carriers stimulated the HBs-specific B cell response in HBs vaccine recipients. Otherwise, isolated T helper cells could never provide sufficient help to induce the HBs-specific B cell responses in chronic HBV carriers. Furthermore, peripheral blood mononuclear cells (PBMC) of six out of 10 vaccine recipients, one out of five HBV-immunized patients, but of no chronic HBV carrier showed a proliferative response to different HBs antigen preparations. This study demonstrated a high frequency of circulating anti-HBs-producing B cells in the early phase of acute HBV infection, but a lower frequency of HBs-specific B cells years after resolution of HBV infection. In chronic HBV carriers. However, deficient HBs-specific T and B cell responses were observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697635      PMCID: PMC2200470          DOI: 10.1046/j.1365-2249.1996.d01-732.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  The study of efficacy of lamivudine in patients with severe acute hepatitis B.

Authors:  Jian-Wu Yu; Li-Jie Sun; Yong-Hua Zhao; Peng Kang; Shu-Chen Li
Journal:  Dig Dis Sci       Date:  2009-12-03       Impact factor: 3.199

2.  Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients.

Authors:  Xiangsheng Xu; Qinghua Shang; Xinyue Chen; Weimin Nie; Zhengsheng Zou; Ang Huang; Ming Meng; Lei Jin; Ruonan Xu; Ji-Yuan Zhang; Junliang Fu; Lifeng Wang; Zirong Tang; Yunbo Xie; Xiaoming Yang; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-04-06       Impact factor: 11.530

Review 3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 4.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

6.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

7.  Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo.

Authors:  W O Böcher; H Marcus; R Shakarchy; B Dekel; D Shouval; E Galun; Y Reisner
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

8.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Authors:  Catherine A Blish; Ozge C Dogan; Nina R Derby; Minh-An Nguyen; Bhavna Chohan; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Authors:  Loghman Salimzadeh; Nina Le Bert; Charles-A Dutertre; Upkar S Gill; Evan W Newell; Christian Frey; Magdeleine Hung; Nikolai Novikov; Simon Fletcher; Patrick Tf Kennedy; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2018-08-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.